Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osi Pharmaceuticals has initiated the first-in-human clinical study of its development compound PSN602, an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.
Subscribe to our email newsletter
The double-blind, placebo-controlled, ascending, single and multiple, oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN602 in healthy lean and obese subjects, as well as on the effects of PSN602 on appetite and food intake in healthy obese subjects.
Anker Lundemose, president of Osi, said: “Our research efforts are focused on designing innovative, next-generation, small molecule compounds to provide safer or more effective options for the treatment of type 2 diabetes and obesity.”